SCHEMBL1248823

SCHEMBL1248823

O=C1NC(=O)C(=Cc2cccc3ccccc23)S1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 1.00
MEN1 O00255 5/20 1.00
TTR P02766 3/20 1.00
AKR1B1 P15121 1/20 1.00
PIM1 P11309 4/20 0.74
NAT1 P18440 1/20 0.63
IGF1R P08069 1/20 0.63
GSK3B P49841 3/20 0.58
PIM2 Q9P1W9 3/20 0.58
PIM3 Q86V86 2/20 0.58
TDP2 O95551 1/20 0.57
CASP7 P55210 1/20 0.57
CASP9 P55211 1/20 0.57
CASP6 P55212 1/20 0.57
CASP8 Q14790 1/20 0.57
CISD1 Q9NZ45 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.54
SIRT1 Q96EB6 1/20 0.54
ALDH1A1 P00352 3/20 0.52
PLA2G1B P04054 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1248821 1.00 KMT2A (1.00) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1247506 0.85 PIM1 (1.00) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL8181784 0.85 KMT2A (0.74) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1247507 0.85 PIM1 (1.00) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1248790 0.82 TTR (0.70) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1248791 0.82 TTR (0.70) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL15101827 0.82 TTR (0.69) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1247563 0.79 AKR1B1 (0.66) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1247562 0.79 AKR1B1 (0.66) KMT2AMEN1TTRAKR1B1PIM1
SCHEMBL1250141 0.79 NAT1 (0.68) KMT2AMEN1TTRAKR1B1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20080280814-A1 Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide NOVO NORDISK A/S (DK) 2008-11-13 US disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 EP disclosed
EP-1791554-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN AND INSULINOTROPIC PEPTIDE Novo Nordisk A/S (DK) 2007-06-06 EP disclosed
EP-1429763-B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-05-30 EP disclosed
EP-1768694-A1 PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN NOVO NORDISK A/S (DK) 2007-04-04 EP disclosed
US-20060258561-A1 Novel NPH insulin preparations NOVO NORDISK A/S (DK) 2006-11-16 US disclosed
WO-2006082245-A1 PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND NOVO NORDISK A/S (DK) 2006-08-10 WO disclosed
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin NOVO NORDISK A/S (DK) 2006-03-30 US disclosed
EP-1605967-A1 NOVEL NPH INSULIN PREPARATIONS NOVO NORDISK A/S (DK) 2005-12-21 EP disclosed
EP-1585541-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2005-10-19 EP disclosed
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability NOVO NORDISK A/S (DK) 2005-03-24 US disclosed
WO-2004080481-A1 NOVEL NPH INSULIN PREPARATIONS NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004080480-A1 PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004056347-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed
EP-1429763-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-06-23 EP disclosed
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer NOVO NORDISK A/S (DK) 2003-12-11 US disclosed
WO-2003027081-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2003-04-03 WO disclosed
WO-2000018746-A1 THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280814-A1 Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide IAPP, GPR119, INSR KMT2A 4725/4885MEN1 66/4885TTR 134/4885
US-20060258561-A1 Novel NPH insulin preparations IAPP, HBB, INSR KMT2A 4399/4885MEN1 680/4885TTR 31/4885
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin IAPP, GPR119, INSR KMT2A 4638/4885MEN1 395/4885TTR 33/4885
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer IAPP, IRS1, GPR119 KMT2A 4685/4885MEN1 863/4885TTR 198/4885
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability IAPP, IRS1, INSR KMT2A 4420/4885MEN1 299/4885TTR 84/4885
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB KMT2A 4327/4885MEN1 912/4885TTR 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.